1.Organic carbon monoxide prodrug, BW-CO-111, in protection against chemically-induced gastric mucosal damage.
Dominik BAKALARZ ; Marcin SURMIAK ; Xiaoxiao YANG ; Dagmara WÓJCIK ; Edyta KORBUT ; Zbigniew ŚLIWOWSKI ; Grzegorz GINTER ; Grzegorz BUSZEWICZ ; Tomasz BRZOZOWSKI ; Jakub CIESZKOWSKI ; Urszula GŁOWACKA ; Katarzyna MAGIEROWSKA ; Zhixiang PAN ; Binghe WANG ; Marcin MAGIEROWSKI
Acta Pharmaceutica Sinica B 2021;11(2):456-475
Metal-based carbon monoxide (CO)-releasing molecules have been shown to exert anti-inflammatory and anti-oxidative properties maintaining gastric mucosal integrity. We are interested in further development of metal-free CO-based therapeutics for oral administration. Thus, we examine the protective effect of representative CO prodrug, BW-CO-111, in rat models of gastric damage induced by necrotic ethanol or aspirin, a representative non-steroidal anti-inflammatory drug. Treatment effectiveness was assessed by measuring the microscopic/macroscopic gastric damage area and gastric blood flow by laser flowmetry. Gastric mucosal mRNA and/or protein expressions of HMOX1, HMOX2, nuclear factor erythroid 2-related factor 2, COX1, COX2,